Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation.
Tom C ZwartSuzanne BezstarostiFederica R AchiniMarlies E J ReindersMarco W SchilhamSebastiaan HeidtHenk-Jan GuchelaarJohan W de FijterDirk Jan A R MoesPublished in: British journal of clinical pharmacology (2022)
Alemtuzumab displays substantial pharmacokinetic variability in kidney transplant recipients, which may warrant a personalised treatment strategy. Lean bodyweight-adjusted dosing poses an option for individualised dosing, but further evaluation of its potential clinical benefit is warranted.